London, UK; Brentwood, TN, US; 27 March 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces the enrolment of the first patient in a clinical study to investigate the use of OncoGel™, a novel formulation of paclitaxel for local administration, as an adjuvant treatment to surgical removal of the tumour in patients with recurrent glioblastoma multiforme (GBM).
